Treatment of Non-ischemic Cardiomyopathies by Intravenous Extracellular Vesicles of Cardiovascular Progenitor Cells

This trial is testing an experimental treatment using extracellular vesicles (tiny particles secreted by heart progenitor cells) given intravenously for people with dilated cardiomyopathy — a condition where the heart muscle becomes enlarged and weak, reducing its ability to pump blood. The treatment aims to help the heart muscle recover. **You may be eligible if...** - You are between 18 and 80 years old - You have dilated cardiomyopathy with a significantly reduced heart pumping function (ejection fraction of 40% or less) - The weakened heart is not explained by blocked arteries, high blood pressure, or valve disease - If caused by chemotherapy, you have been cancer-free for at least 2 years - You have French social security coverage **You may NOT be eligible if...** - Your heart failure is caused by coronary artery disease, severe valve disease, or uncontrolled high blood pressure - You have active cancer or have been in remission less than 2 years - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.